Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma
Public ClinicalTrials.gov record NCT00003715. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Randomized, Open-Label, Comparative Clinical Trial in Post-Surgical Melanoma Patients With Either DNP-Modified Autologous Tumor Vaccine or Interferon Alpha-2b
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of melanoma vaccine with that of interferon alfa-2b in treating patients who have stage III melanoma that has spread to regional lymph nodes following surgery.
Study identification
- NCT ID
- NCT00003715
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 425 participants
Conditions and interventions
Conditions
Interventions
- BCG vaccine Biological
- autologous tumor cell vaccine Biological
- recombinant interferon alfa Biological
- chemotherapy Drug
- cyclophosphamide Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 1998 (Type not available)
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Dec 3, 2015
Started 1998
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cancer and Blood Institute of the Desert | Rancho Mirage | California | 92270 | — |
| Yale Comprehensive Cancer Center | New Haven | Connecticut | 06520-8028 | — |
| Columbia - HCA Cancer Research Network | North Miami Beach | Florida | 33180 | — |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Georgia Cancer Specialists | Decatur | Georgia | 30033 | — |
| University of Illinois at Chicago | Chicago | Illinois | 60612 | — |
| Lutheran General Cancer Care Center | Park Ridge | Illinois | 60068 | — |
| James Graham Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Cancer and Hematology Centers of Western Michigan | Grand Rapids | Michigan | 49546 | — |
| Hubert H. Humphrey Cancer Center | Robbinsdale | Minnesota | 55422 | — |
| Midwest Oncology Consortium | Kansas City | Missouri | 64111 | — |
| Jersey Shore Cancer Center | Neptune City | New Jersey | 07753 | — |
| Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| Herbert Irving Comprehensive Cancer Center | New York | New York | 10032 | — |
| University of Pennsylvania Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| Kimmel Cancer Center of Thomas Jefferson University - Philadelphia | Philadelphia | Pennsylvania | 19107 | — |
| Palmetto Hematology/Oncology Associates | Spartanburg | South Carolina | 29303 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00003715, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2015 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00003715 live on ClinicalTrials.gov.